Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – Still a Buy?

Pharming Group (NASDAQ:PHAR) shares saw unusually-strong trading volume on Tuesday . Approximately 5,054 shares traded hands during mid-day trading, a decline of 19% from the previous session’s volume of 6,208 shares.The stock last traded at $11.20 and had previously closed at $10.75.

Analysts Set New Price Targets

A number of research analysts recently weighed in on PHAR shares. Oppenheimer upped their price target on Pharming Group from $30.00 to $39.00 and gave the stock an “outperform” rating in a research note on Friday, March 14th. HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 20th.

Pharming Group Stock Down 1.9%

The business’s fifty day moving average price is $9.70 and its two-hundred day moving average price is $9.20. The stock has a market capitalization of $755.82 million, a PE ratio of -42.73 and a beta of 0.02. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The firm had revenue of $79.09 million during the quarter, compared to the consensus estimate of $67.74 million. On average, equities research analysts forecast that Pharming Group will post -0.2 EPS for the current fiscal year.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.